DUBLIN--(BUSINESS WIRE)--The "Global Gene Therapy Market (2022-2027) by Type, Vector Type, Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis." report has been added to ResearchAndMarkets.com's offering.
The Global Gene Therapy Market is estimated to be USD 4.56 Bn in 2022 and is expected to reach USD 13.76 Bn by 2027, growing at a CAGR of 24.72%.
Market Dynamics
Drivers
- Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
- Government Support and Ethical Acceptance of Gene Therapy For Treatments
- Restraints
- High Costs Associated with Gene Therapies
Opportunities
- Research & Development in Orphan Diseases and Advancements in Gene Therapy
- Favorable Regulatory Approvals
- Favorable Payment Conditions
Challenges
- Side Effects and Moral Concerns Regarding New Gene Therapy
Market Segmentations
The Global Gene Therapy Market is segmented based on Type, Vector Type, Application, and Geography.
- By Type, the market is classified into Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy, Suicide Gene Therapy, and Tumor Suppressor Gene Therapy.
- By Vector Type, the market is classified into Non-viral Vectors, Viral Vectors.
- By Application, the market is classified into Cardiovascular Diseases, Genetic Diseases, Infectious Diseases, Neurological Diseases, and Oncological Disorders.
- By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.
Countries Studied
- America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
- Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
- Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
- Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)
Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Ansoff Analysis
The report presents a detailed Ansoff matrix analysis for the Global Gene Therapy Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
The analyst analyses the Global Gene Therapy Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.
Key Topics Covered:
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Dynamics
5 Market Analysis
6 Global Gene Therapy Market, By Type
7 Global Gene Therapy Market, By Vector Type
8 Global Gene Therapy Market, By Application
9 Americas' Gene Therapy Market
10 Europe's Gene Therapy Market
11 Middle East and Africa's Gene Therapy Market
12 APAC's Gene Therapy Market
13 Competitive Landscape
14 Company Profiles
15 Appendix
Companies Mentioned
- AGC Biologics.
- Abeona Therapeutics Inc.
- Adaptimmune Therapeutics PLC
- Alnylam Pharmaceuticals, Inc.
- American Gene Technologies Inc.
- Amgen Inc.
- AnGes, Inc.
- Applied Genetic Technologies Corporation
- Astellas Gene Therapies
- Biogen Inc.
- Bluebird Bio, Inc.
- Cellectis, Inc.
- Editas Medicine, Inc.
- Human Stem Cells Institute
- Ionis Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Mustang Bio
- Novartis AG
- Orchard Therapeutics PLC
- Poseida Therapeutics, Inc.
- Sangamo Therapeutics, Inc.
- Sarepta Therapeutics, Inc.
- Shenzhen SiBiono GeneTech Co. Ltd.
- Spark Therapeutics, Inc.
- Uniqure N.V.
For more information about this report visit https://www.researchandmarkets.com/r/1lrptf
